ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

doi:10.3748/wjg.14.6401

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3248)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

331

HTML

2489

Figures (1-5)

229

Tables (1-2)

199

Sum=3248

Nov 7, 2008 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 7, 2008; 14(41): 6401-6407
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401

Full Size Figure Download Figure

Figure 1 Genotyping results of ERCC1 codon 118 polymorphism electrophoresis results of PCR-LDR products with different genotypes and its sequencing results. LDR products of ERCC1 118 C/C and T/T were 92 and 97 base pairs. The SNP sites are indicated by the arrowhead. The results were completely matched to the corresponding results derived from PCR-LDR.

Citation: Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008; 14(41): 6401-6407
URL: https://www.wjgnet.com/1007-9327/full/v14/i41/6401.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6401